Madrigal Pharmaceuticals, Inc.
MDGL
$307.78
-$13.32-4.15%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 66.18% | 324.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 66.18% | 324.75% | |||
| Cost of Revenue | 60.08% | 238.36% | |||
| Gross Profit | 66.39% | 328.67% | |||
| SG&A Expenses | 31.27% | 2.03% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -4.57% | 0.74% | |||
| Operating Income | 42.40% | 28.44% | |||
| Income Before Tax | 44.45% | 29.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 44.45% | 29.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 44.45% | 29.62% | |||
| EBIT | 42.40% | 28.44% | |||
| EBITDA | 42.56% | 28.51% | |||
| EPS Basic | 44.92% | 30.73% | |||
| Normalized Basic EPS | 44.92% | 30.73% | |||
| EPS Diluted | 44.92% | 30.73% | |||
| Normalized Diluted EPS | 44.92% | 30.73% | |||
| Average Basic Shares Outstanding | 0.84% | 1.60% | |||
| Average Diluted Shares Outstanding | 0.84% | 1.60% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||